New Funding Rounds for 11 AI Pharmaceutical Companies in May

04 Jun 2024
www.echemi.com
In May 2024, a total of 11 AI-driven pharmaceutical companies around the world raised new rounds of funding, amounting to approximately 2.021 billion Chinese yuan (about $290 million USD) in disclosed investments.
On the domestic front in China, two local AI pharma companies secured new funding. Shanghai-based Biaoxin Biotech raised funds in a Series A round, while Taizhou Xingputai Biotech received strategic investment worth tens of millions. Biaoxin, a spin-off from the Shanghai Institute of Immunochemistry, is developing oral protein degradation small molecule drugs using AI and machine learning models combined with high-throughput experimental data to guide drug design. The company currently has two molecular glue degrader drug candidates in clinical stages. Xingputai, founded by Shengpuze Tai in 2019, is a peptide-based new drug R&D company that integrates AI-powered drug discovery technology and green peptide synthesis.
Looking globally, the largest funding amount this month went to U.S. company Karius, which raised $100 million in a Series C round. Karius is using AI to disrupt traditional diagnostics, aiming to reduce the spread of antibiotic resistance by rapidly detecting pathogens from a single blood sample. Another early-stage U.S. startup, OverTBio founded by NYU professors, secured $16 million in a seed funding. OverTBio is a data-driven company developing gene-engineered immune cell therapies. Additionally, protein design startup NablaBio raised $26 million in Series A financing and announced strategic collaborations worth over $550 million with pharmaceutical giants AstraZeneca, Bristol Myers Squibb, and Takeda.
Across the Atlantic, the U.K.-based LabGenius, an AI-powered protein therapy developer, successfully closed a $44.51 million Series B round. Meanwhile, Hungary's Turbine, which uses AI to simulate cancer mechanisms and test potential drugs, also secured a new funding round.
This surge in AI pharma investments underscores the growing adoption of advanced technologies to drive innovation in drug discovery and development, with the potential to improve diagnostic capabilities and therapy options for patients.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
[+6]
Indications
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.